Potential impact of different Cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity

Clinical and Vaccine Immunology

Volumn 21, Issue 6, 2014, Pages 813-816

  Prince, Harry E ^a   Lape ́Nixon, Mary ^a   Brenner, Andrew ^b   Pitstick, Nancy ^c   Couturier, Marc Roger ^d,e  

^a Focus Diagnostics   (United States)

^b Mayo Medical Laboratories   (United States)

^c ARUP LABORATORIES   (United States)

^d ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; DIAGNOSTIC KIT; IMMUNOGLOBULIN M; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BINDING AFFINITY; CHEMILUMINESCENCE IMMUNOASSAY; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VIRAL DISEASE IMMUNOFLUORESCENCE ASSAY; VIRUS ATTACHMENT; ALGORITHM; ANTIBODY AFFINITY; BLOOD; CYTOMEGALOVIRUS INFECTIONS; DIAGNOSTIC KIT; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LUMINESCENCE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REAGENT KITS, DIAGNOSTIC; YOUNG ADULT;

EID: 84901625123     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00106-14     Document Type: Article

References (21)

1. Bodéus M, Feyder S, Goubau P. 1998. Avidity of IgG antibodies distinguishes primary from nonprimary cytomegalovirus infection in pregnant women. Clin. Diagn. Virol. 9:9-16. http://dx.doi.org/10.1016/S0928-0197(97) 10016-2. (Pubitemid 28153242)
2. Grangeot-Keros L, Mayaux MJ, Lebon P, Freymuth F, Eugene G, Stricker R, Dussaix E. 1997. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women. J. Infect. Dis. 175:944-946. http://dx.doi.org/10.1086/513996. (Pubitemid 27142973)
3. Dollard SC, Grosse SD, Ross DS. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 17:355-363. http://dx.doi.org/10. 1002/rmv.544. (Pubitemid 47425872)
4. Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP. 1997. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin. Diagn. Lab. Immunol. 4:469-473. (Pubitemid 27321782)
5. Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. 2008. New advances in the diagnosis of congenital cytomegalovirus infection. J. Clin. Virol. 41:192-197. http://dx.doi.org/10.1016/j.jcv.2007.10.015. (Pubitemid 351246738)
6. Revello MG, Fabbri E, Furione M, Zavattoni M, Lilleri D, Tassis B, Quarenghi A, Cena C, Arossa A, Montanari L, Rognoni V, Spinillo A, Gerna G. 2011. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. J. Clin. Virol. 50:303-307. http://dx.doi.org/10.1016/j.jcv.2010.12. 012.
7. Lazzarotto T, Spezzacatena P, Varani S, Gabrielli L, Pradelli P, Guerra B, Landini MP. 1999. Anticytomegalovirus (anti-CMV) immunoglobulin G avidity in identification of pregnant women at risk of transmitting congenital CMV infection. Clin. Diagn. Lab. Immunol. 6:127-129. (Pubitemid 29035651)
8. Munro SC, Hall B, Whybin LR, Leader L, Robertson P, Maine GT, Rawlinson WD. 2005. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J. Clin. Microbiol. 43:4713-4718. http://dx.doi.org/10.1128/JCM.43.9. 4713-4718.2005. (Pubitemid 41298268)
9. Enders G, Daiminger A, Bäder U, Exler S, Schimpf Y, Enders M. 2013. The value of CMV IgG avidity and immunoblot for timing the onset of primaryCMVinfection in pregnancy. J. Clin. Virol. 56:102-107. http://dx.doi.org/10.1016/j.jcv.2012.09.015.
10. Bodéus M, Beulné D, Goubau P. 2001. Ability of three IgG-avidity assays to exclude recent cytomegalovirus infection. Eur. J. Clin. Microbiol. Infect. Dis. 20:248-252. http://dx.doi.org/10.1007/s100960100484. (Pubitemid 32477242)
11. Lazzarotto T, Varani S, Guerra B, Nicolosi A, Lanari M, Landini MP. 2000. Prenatal indicators of congenital cytomegalovirus infection. J. Pediatr. 137:90-95. http://dx.doi.org/10.1067/mpd.2000.107110. (Pubitemid 30470929)
12. Dollard SC, Staras SAS, Amin MM, Scott Schmid D, Cannon MJ. 2011. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin. Vaccine Immunol. 18:1895-1899. http://dx.doi.org/10.1128/CVI.05228-11.
13. Macé M, Sissoeff L, Rudent A, Grangeot-Keros L. 2004. A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women. Prenat. Diagn. 24:861-863. http://dx.doi.org/10.1002/pd.1001. (Pubitemid 39576798)
14. Prince HE, Leber AL. 2002. Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels. Clin. Diagn. Lab. Immunol. 9:824-827. http://dx.doi.org/10. 1128/CDLI.9.4.824-827.2002. (Pubitemid 34773885)
15. Lazzarotto T, Galli C, Pulvirenti R, Rescaldani R, Vezzo R, La Gioia A, Martinelli C, La Rocca S, Agresti G, Grillner L, Nordin M, van Ranst M, Combs B, Maine GT, Landini MP. 2001. Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulinM(IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay. Clin. Diagn. Lab. Immunol. 8:196-198. http://dx.doi.org/10.1128/CDLI.8.1.196-198.2001. (Pubitemid 32065677)
16. Prince HE, Lapé-Nixon M, Novak-Weekley SM. 2014. Performance of a cytomegalovirus immunoglobulin G enzyme immunoassay kit modified to measure avidity. Clin. Vaccine Immunol. 21:808-812. http://dx.doi.org/10.1128/CVI.00105- 14.
17. De Paschale M, Agrappi C, Manco MT, Clerici P. 2010. Positive predictive value of anti-HCMV IgM as an index of primary infection. J. Virol. Methods 168:121-125. http://dx.doi.org/10.1016/j.jviromet.2010.05.001.
18. Binnicker MJ, Jespersen DJ, Harring JA. 2010. Multiplex detection of IgM and IgG class antibodies to Toxoplasma gondii, rubella virus, and cytomegalovirus using a novel multiplex flow immunoassay. Clin. Vaccine Immunol. 17:1734-1738. http://dx.doi.org/10.1128/CVI.00332-10.
19. Lagrou K, Bodeus M, Van Ranst M, Goubau P. 2009. Evaluation of the new Architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J. Clin. Microbiol. 47:1695-1699. http://dx.doi.org/10.1128/JCM.02172-08.
20. Carlier P, Harika N, Bailly R, Vranken G. 2010. Laboratory evaluation of the new Access cytomegalovirus immunoglobulin M and IgG assays. J. Clin. Virol. 49:192-197. http://dx.doi.org/10.1016/j.jcv.2010.07.024.
21. Bal TA, Armstrong G, Han XY. 2012. Evaluation of the IMMULITE 2000 CMV IgM assay. Herpesviridae 3:2-6. http://dx.doi.org/10.1186/2042-4280-3-2.